Held by 4 specialist biotech funds
High ConvergenceRock Springs' $1.7M initiating position in ACADIA likely reflects conviction in pimavanserin's commercial trajectory or upcoming catalysts—potentially label expansions (dementia-related psychosis showed promise in trials) or Q3/Q4 revenue inflection following the company's pivot to specialty pharma focus.
AI analyst context — unlock full analysis
## Signal Note: Baker Bros. Initiates Massive ACAD Position **Flag: The reported position size (~$1.15 trillion) is almost certainly a data error — ACAD's entire market cap is ~$3-4B. This likely reflects an incorrect share count or pricing artifact in the 13F filing and requires verification before any action.** That said, if Baker Bros. has taken a meaningful new stake in ACAD, the signal is noteworthy. ACAD's primary value driver is **Nuplazid (pimavanserin)**, the only FDA-approved treatment for Parkinson's disease psychosis, generating ~$550M+ annually, alongside pipeline expansion into **negative symptoms of schizophrenia** and broader neuropsychiatric indications. Baker Bros.' concentrated, high-conviction style — typically initiating positions only when they see asymmetric clinical/commercial upside — suggests
+ 2more — see how much conviction went in
See the Full Story